CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Capricor Therapeutics, Inc. (CAPR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Capricor Therapeutics, Inc. (CAPR)

Pharmaceutical Preparations · market cap $514M · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-22
PDUFA
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Capricor Therapeutics (CAPR) is a ~$423M market-cap, 160-employee company whose value rests on deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy (DMD) with orphan and fast-track designations. Its PDUFA date is 2026-11-22, which our calendar rates 9/10 in importance, and Q3 earnings are estimated for 2026-11-09. Several pipeline entries in our data (CAP-1002, 'Allogeneic Cardiosphere-Derived Cells (CAP-1002)' and 'Deramiocel (CAP-1002)') appear to be the same asset, so the pipeline is effectively deramiocel plus earlier-stage CAP-2003 (COVID-19 cardiac, Phase 2) and cenderitide (heart failure, Phase 2).
The catalyst path
  • 2026-11-22PDUFA · Deramiocel (CAP-1002)imp 9/10
Pipeline
AssetPhaseIndication
CAP-1002Phase 3Duchenne Muscular Dystrophy
CAP-2003Phase 2COVID-19 Cardiac
DeramiocelPhase 3Muscular Dystrophies
CenderitidePhase 2Heart Failure
Allogeneic Cardiosphere-Derived Cells (CAP-1002)Phase 2Duchenne Muscular Dystrophy
Deramiocel (CAP-1002)Phase 3Duchenne Muscular Dystrophy
Price & technical context
3-month
+24.7%
6-month
-68.5%
12-month
+53.0%
52-wk range
$3.85–$35.34
vs 50-day MA
+9.2%
vs 200-day MA
-55.6%
Realized vol
218.4%
Max drawdown
-89.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for CAPR (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.